Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
A correction – as long as it is not too severe – might not be a bad thing for the sector.
But how long can the money keep rolling in?